Brief: 3D Medicines Inc Enters Strategic Agreement With Catug Biotechnology
20/08/2025 15:54
Aug 20 (Reuters) - 3D Medicines Inc 1244.HK: ENTERS STRATEGIC AGREEMENT WITH CATUG BIOTECHNOLOGY PARTIES TO LEVERAGE MRNA R+D PLATFORM Further company coverage: 1244.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on 3D Medicines
See all newsBrief: 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
Brief: 3D Medicines Inc Says Zhang Jing Resigns As CFO
Brief: 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
Brief: 3D Medicines Says Envafoimab Granted Orphan Drug Designation
Brief: 3D Medicines Inc Enters Strategic Agreement With Catug Biotechnology